Figure 4From: An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophreniaMean change in z scores for body weight (A) and body mass index (B) over the course of the study for the PBO/RIS group, RIS/RIS group, and all subjects. Data are presented for all subjects to the 6- or 12-month end point. The RIS/RIS 6- and 12-month groups are mutually exclusiveBack to article page